Clinical trial Phase 3 Interventional Ages 18 and up

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Run by ArriVent BioPharma, Inc. · NCT05607550 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-10-06.

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment398 (actual)
SponsorArriVent BioPharma, Inc.
Industry-sponsored
Drugs / interventionsfurmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
Locations208 sites (Australia, Brazil, Canada, China, France, Israel, Italy, Japan and more)
Trial IDNCT05607550 on ClinicalTrials.gov

Who can join: the full rules

Show full inclusion / exclusion criteria
Key Inclusion Criteria:

* Histologically or cytologically documented, locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
* Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation in tumor tissue or blood from local or central testing.
* No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal antibodies, or bispecific antibodies).
* Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease (excluding EGFR-TKIs) must have experienced a treatment free interval of at least 12 months.
* Patients with a history of treated CNS metastases or new asymptomatic CNS metastases are eligible.

Where it's running

  • Arrivent Investigative Site
    Daphne, Alabama, United States
  • Arrivent Investigative Site
    Yuma, Arizona, United States
  • Arrivent Investigative Site
    Fayetteville, Arkansas, United States
  • Arrivent Investigative Site
    Beverly Hills, California, United States
  • Arrivent Investigative Site
    Fullerton, California, United States
  • Arrivent Investigative Site
    Long Beach, California, United States
Show 44 more locations
  • Arrivent Investigative Site
    Los Alamitos, California, United States
  • Arrivent Investigative Site
    Napa, California, United States
  • Arrivent Investigative Site
    Orange, California, United States
  • Arrivent Investigative Site
    Orange, California, United States
  • Arrivent Investigative site
    Sacramento, California, United States
  • Arrivent Investigative Site
    San Diego, California, United States
  • Arrivent Investigative Site
    Santa Barbara, California, United States
  • Arrivent Investigative Site
    Santa Monica, California, United States
  • Arrivent Investigative Site
    Santa Rosa, California, United States
  • Arrivent Investigative Site
    Whittier, California, United States
  • Arrivent Investigative Site
    Hartford, Connecticut, United States
  • Arrivent Investigative Site
    Norwich, Connecticut, United States
  • Arrivent Investigative Site
    Fort Myers, Florida, United States
  • Arrivent Investigative Site
    St. Petersburg, Florida, United States
  • Arrivent Investigative Site
    The Villages, Florida, United States
  • Arrivent Investigative Site
    Peoria, Illinois, United States
  • Arrivent Investigative Site
    Rolling Meadows, Illinois, United States
  • Arrivent Investigative Site
    Fort Wayne, Indiana, United States
  • Arrivent Investigative Site
    Indianapolis, Indiana, United States
  • Arrivent Investigative Site
    South Bend, Indiana, United States
  • Arrivent Investigative Site
    Bethesda, Maryland, United States
  • Arrivent Investigative Site
    Frederick, Maryland, United States
  • Arrivent Investigative Site
    Rockville, Maryland, United States
  • Arrivent Investigative Site
    Fairhaven, Massachusetts, United States
  • Arrivent Investigative Site
    Lansing, Michigan, United States
  • Arrivent Investigative Site
    Bolivar, Missouri, United States
  • Arrivent Investigative Site
    Kansas City, Missouri, United States
  • Arrivent Investigative Site
    Saint Joseph, Missouri, United States
  • Arrivent Investigative Site
    St Louis, Missouri, United States
  • Arrivent Investigative Site
    Omaha, Nebraska, United States
  • Arrivent Investigative Site
    Belleville, New Jersey, United States
  • Arrivent Investigative Site
    Englewood, New Jersey, United States
  • Arrivent Investigative Site
    Florham Park, New Jersey, United States
  • Arrivent Investigative Site
    The Bronx, New York, United States
  • Arrivent Investigative Site
    Goldsboro, North Carolina, United States
  • ArriVent Investigative Site
    Pinehurst, North Carolina, United States
  • Arrivent Investigative Site
    Canton, Ohio, United States
  • Arrivent Investigative Site
    Cincinnati, Ohio, United States
  • ArriVent Investigative Site
    Cincinnati, Ohio, United States
  • Arrivent Investigative Site
    Cleveland, Ohio, United States
  • Arrivent Investigative Site
    Columbus, Ohio, United States
  • Arrivent Investigative Site
    Oklahoma City, Oklahoma, United States
  • Arrivent Investigative Site
    Tulsa, Oklahoma, United States
  • Arrivent Investigative Site
    Salem, Oregon, United States

+158 more sites. See ClinicalTrials.gov for the full list.

Study contacts

  • Principal investigator: Jamuna Thimmarayappa — ArriVent BioPharm

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.